Results 21 to 30 of about 7,329,727 (241)

Expert Consensus on Single-Inhaler Triple Therapy for the Treatment of Asthma in Adult Patients. [PDF]

Open Respir Arch
Despite existing guidelines, many patients with asthma do not achieve adequate control of their disease. This is largely due to low adherence to inhaled therapy. Single-inhaler administration may improve this and other aspects of asthma therapy, such as cost-effectiveness.
Serrano CC, Moragón EM, Padilla-Galo A, Aracil CF, Alonso AT, Chica GP, Bastida AP, Falcón AR, Carretero-Gracia JÁ, Soto-Campos JG, Members of the Validation Task Force.   +10 more
europepmc   +4 more sources

Preventing clinically important deterioration with single-inhaler triple therapy in COPD [PDF]

ERJ Open Research, 2018
Clinically important deterioration (CID) is a novel composite end-point (lung function, health status, exacerbations) for assessing disease stability in patients with chronic obstructive pulmonary disease (COPD).
Ian Naya, Chris Compton, Afisi S. Ismaila, Ruby Birk, Noushin Brealey, Maggie Tabberer, Chang-Qing Zhu, David A. Lipson, Gerard Criner   +8 more
doaj   +4 more sources

Pulmonary outcomes of incretin-based therapies in COPD patients receiving single-inhaler triple therapy. [PDF]

ERJ Open Res
BackgroundPatients with COPD on triple therapy often face exacerbations and comorbidities. Emerging evidence suggests that glucagon-like peptide-1 (GLP-1) analogues may reduce the risk of exacerbation in patients with COPD and type 2 diabetes mellitus (T2DM).
See XY, Xanthavanij N, Lee YC, Ong TE, Wang TH, Ahmed O, Chang YC, Peng CY, Chi KY, Chang Y, Chang KY, Chiang CH.   +11 more
europepmc   +4 more sources

Comparison of treatment persistence, adherence, and risk of exacerbation in patients with COPD treated with single-inhaler versus multiple-inhaler triple therapy: A prospective observational study in China

Frontiers in Pharmacology, 2023
Aim: This study sought to compare treatment persistence, adherence, and risk of exacerbation among patients with COPD treated with single-inhaler triple therapy (SITT) and multiple-inhaler triple therapy (MITT) in the Chinese population.Methods: This was
Ling Lin, Ling Lin, Ling Lin, Cong Liu, Cong Liu, Cong Liu, Wei Cheng, Wei Cheng, Wei Cheng, Qing Song, Qing Song, Qing Song, Yuqin Zeng, Yuqin Zeng, Yuqin Zeng, Xin Li, Dingding Deng, Dan Liu, Yan Chen, Yan Chen, Yan Chen, Shan Cai, Shan Cai, Shan Cai, Ping Chen, Ping Chen, Ping Chen   +26 more
doaj   +3 more sources

Adherence and Persistence to Single-Inhaler Versus Multiple-Inhaler Triple Therapy for Asthma Management

Journal of Allergy and Clinical Immunology: in Practice, 2022
Treatment guidelines recommend triple therapy for patients with asthma who remain uncontrolled on inhaled corticosteroid/long-acting β2-agonist therapy. Previously, triple therapy was only available via multiple inhalers. Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) is approved as maintenance treatment for asthma; however ...
Sean MacKnight, Mei Sheng Duh, Young Jung   +2 more
exaly   +3 more sources

Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple Therapy in Spain: IMPACT Trial

International Journal of Chronic Obstructive Pulmonary Disease, 2022
Given between-country differences in healthcare systems, treatment costs, and disease management guidelines, country-specific cost-effectiveness analyses are important. This study evaluated the cost-effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI and UMEC/VI among patients with symptomatic chronic ...
Victoria Federico Paly, Laura Amanda Vallejo-Aparicio, Alan Martin, José Luis Izquierdo, Juan Antonio Riesco, Juan José Soler-Cataluña, Catarina Abreu, Chandroday Biswas, Afisi S Ismaila   +8 more
openaire   +6 more sources

Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study. [PDF]

Adv Ther, 2020
The phase 3 InforMing the PAthway of COPD (chronic obstructive pulmonary disease) Treatment (IMPACT) trial, single-inhaler therapy with fluticasone furoate (FF) 100 μg, umeclidinium (UMEC) 62.5 μg, and vilanterol (VI) 25 μg demonstrated a reduction in the rate of moderate or severe exacerbations compared with FF/VI or UMEC/VI in patients with ...
Tabberer M, Jones CE, Kilbride S, Halpin DMG, Lomas DA, Pascoe S, Singh D, Wise RA, Criner GJ, Lange P, Dransfield MT, Han MK, Martinez FJ, Kaisermann MC, Lipson DA.   +14 more
europepmc   +7 more sources

Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses [PDF]

ERJ Open Research, 2018
Triple inhaled corticosteroid (ICS)/long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) therapy is recommended for symptomatic patients with chronic obstructive pulmonary disease (COPD) and at risk of exacerbations.
David M.G. Halpin, Ruby Birk, Noushin Brealey, Gerard J. Criner, Mark T. Dransfield, Emma Hilton, David A. Lomas, Chang-Qing Zhu, David A. Lipson   +8 more
doaj   +5 more sources

Economic impact of implementing prescription of single-inhaler triple therapies versus current multiple-inhaler triple therapies for COPD in the Apulia Region

BMC Health Services Research, 2022
Background The most impacting direct costs associated to COPD for the National Health Systems (NHS) are those related to accesses to the emergency room and hospital admissions, due to the onset of one or more COPD exacerbations.
Emanuela Resta, Giulia Scioscia, Donato Lacedonia, Carla Maria Irene Quarato, Francesco Panza, Onofrio Resta, Giorgia Lepore, Enrico Buonamico, Valentina Di Lecce, Giovanna Elisiana Carpagnano, Maria Pia Foschino Barbaro, Noemi Rossi   +11 more
doaj   +6 more sources

Adherence to single inhaler triple therapy and digital inhalers in Chronic Obstructive Pulmonary Disease: a literature review and protocol for a randomized controlled trial (TRICOLON study) [PDF]

BMC Pulmonary Medicine
Background Medication non-adherence is a significant problem in patients with Chronic Obstructive Pulmonary Disease (COPD). Efforts to address this issue are receiving increased attention.
Liz J. A. Cuperus, Job van der Palen, Arnoud Aldenkamp, Astrid van Huisstede, Erik W. M. A. Bischoff, Job F. M. van Boven, Folkert Brijker, Stephan Dik, Jeroen A. J. M. van Excel, Martijn Goosens, Peter Th. W. van Hal, Jolanda C. Kuijvenhoven, Lisette I. Z. Kunz, Erwin C. Vasbinder, Huib A. M. Kerstjens, Johannes C. C. M. in ’t Veen, the TRICOLON study group   +16 more
doaj   +2 more sources